Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aptevo Therapeutics Inc.

    NASDAQ: APVO · Real-Time Price · USD
    3.04
    0.00 (0.00%)
    At close: Jul 03, 2025, 3:59 PM
    3.00
    -1.32%
    After-hours: Jul 03, 2025, 04:43 PM EDT
    0.00%
    Bid 2.97
    Market Cap 2.16M
    Revenue (ttm) n/a
    Net Income (ttm) -23.7M
    EPS (ttm) -325.05
    PE Ratio (ttm) -0.01
    Forward PE -0.01
    Analyst Buy
    Ask 3.07
    Volume 130,195
    Avg. Volume (20D) 2,372,967
    Open 3.00
    Previous Close 3.04
    Day's Range 2.93 - 3.05
    52-Week Range 2.81 - 485.44
    Beta 5.73

    About APVO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol APVO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for APVO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +81.91%
    Aptevo Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
    1 month ago
    -21.05%
    Aptevo Therapeutics shares are trading lower after the company announced a 1-for-20 reverse stock split.
    news image

    2 weeks ago · accessnewswire.com

    Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

    SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on...

    news image

    2 weeks ago · accessnewswire.com

    Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

    Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipl...

    news image

    2 weeks ago · benzinga.com

    Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

    U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.

    news image

    2 weeks ago · marketwatch.com

    Aptevo More Than Doubles After Favorable Results in Leukemia Study

    Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia s...

    news image

    2 weeks ago · benzinga.com

    Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

    Aptevo Therapeutics Inc APVO stock is surging on Wednesday.

    news image

    2 weeks ago · accessnewswire.com

    Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

    SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its pro...

    news image

    2 weeks ago · accessnewswire.com

    Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

    85% remission rate observed in evaluable frontline AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed ...

    news image

    3 weeks ago · accessnewswire.com

    Aptevo Participating in the BIO International Convention

    SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro...

    news image

    1 month ago · accessnewswire.com

    Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

    SEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding shares ...

    news image

    1 month ago · accessnewswire.com

    Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

    9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination continues to outperform standard doublet benchmark No cytokine rele...

    Add to Watchlist